Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. HUVR:IN
2. TAP
3. DELL
4. ROIV
5. ANET
6. NKE
7. PANW
8. CL
9. SNDK
10. SPG

Go back to Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts
(NASDAQ: VRCA) Delayed: 5.30 -0.06 (1.12%)
Previous Close $5.36    52 Week High $ 
Open $5.28    52 Week Low $ 
Day High $5.53    P/E N/A 
Day Low $5.25    EPS $ 
Volume 12,198